5 reports

Two biosimilar approvals have been withdrawn; one for filgrastim in April 2011 and one for somatropin in May 2012, leaving a total of ## biosimilars approved for use in Europe.

  • Interferon
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited

MARKET ##.

  • Biological Therapy
  • Interferon
  • APAC
  • World
  • Company Sales

The prominent features of this report are - ##.

  • Clinical Trial
  • Cytokine
  • Interferon
  • Neurological Disorder
  • Biogen Idec Inc.
  • and Table 17.87 shows the likely growth for the global G-CSF/ GM-CSF
  • GLOBAL G-CSF/GM-CSF BIOSIMILARS MARKET FORECAST: DISTRIBUTION BY REGION, 2020 AND 2025 (USD BILLION)

FILGRASTIM ##. ##. ##.

  • Interferon
  • North America
  • United States
  • Market Size
  • Sandoz Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Interferon
  • World
  • Product Initiative